Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01616290 · ClinicalTrials.gov registry record · Phase 1

Pilot Study of PRT-201 Following Angioplasty in Patients With Peripheral Artery Disease (PAD)

A Phase 1 study of Peripheral Artery Disease, sponsored by Proteon Therapeutics.

Completed
Registry status
Phase 1
Development phase
14
Enrollment target
2
Study locations

NCT01616290 is a Phase 1 study of Peripheral Artery Disease that has completed, run by Proteon Therapeutics. The registered enrollment target is 14 participants, below the 126-participant average among 50 other Peripheral Artery Disease trials with a reported enrollment target (89% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01616290, a Phase 1 study of Peripheral Artery Disease, has completed, sponsored by Proteon Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
14 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to determine if it is safe and feasible to apply PRT-201 to the adventitia of arteries following successful angioplasty (PTA).

Conditions Studied

Interventions

  • DRUG PRT-201

Study Locations (2)

California

  • San Francisco VA Medical Center - San Francisco
  • University of California, San Francisco Medical Center - San Francisco

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2012-10
Est. Completion 2015-07
Phase Phase 1

Sponsor

Proteon Therapeutics

7 total trials

What the Registry Record Tells You About NCT01616290

The ClinicalTrials.gov registry entry for NCT01616290 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 126-participant average among 50 other Peripheral Artery Disease trials with a reported enrollment target (89% lower). The listed sponsor is Proteon Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Peripheral Artery Disease appearing as the primary indexed condition, and to 1 intervention - of which PRT-201 is the first listed.

NCT01616290 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT01616290 about?

NCT01616290 is a clinical study titled "Pilot Study of PRT-201 Following Angioplasty in Patients With Peripheral Artery Disease (PAD)". The purpose of this study is to determine if it is safe and feasible to apply PRT-201 to the adventitia of arteries following successful angioplasty (PTA).

What is the current status of trial NCT01616290?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2012-10. Estimated completion is 2015-07.

What conditions does trial NCT01616290 study?

This clinical trial studies the following conditions: Peripheral Artery Disease.

What interventions are being tested in trial NCT01616290?

The interventions under investigation include: PRT-201 (DRUG).

Who is sponsoring clinical trial NCT01616290?

This trial is sponsored by Proteon Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01616290 being conducted?

This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Peripheral Artery Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.